QR-504a
Fuchs Endothelial Corneal Dystrophy (FECD)
PreclinicalActive
Key Facts
About ProQR
ProQR Therapeutics is a clinical-stage biotech company developing transformative RNA therapies for genetic diseases, particularly in ophthalmology. The company leverages its innovative Axiomer® RNA editing platform to create oligonucleotide-based treatments that can correct single nucleotides in RNA, offering a potentially safer and more versatile alternative to DNA editing. While facing clinical setbacks with its earlier candidate sepofarsen, ProQR is advancing a new pipeline of RNA editing candidates and maintains a strategic collaboration with Eli Lilly. The company is publicly traded on the NASDAQ.
View full company profile